Boehringer Ingelheim Sp. z o.o.
+ business areaBioPharma R&D+Services
+ annual revenue
2019 – 790,300,000 PLN
2021 – 882,700,000 PLN
2022 – 1,000,000,000 PLN
2023 – 1,200,000,000 PLN
2024 – 1,300,000,000 PLN
+ workforce (estimated if not reported)
2024 - 232
+ depreciation & amortization
2021 – 1,400,000 PLN
2022 – 1,600,000 PLN
2023 – 2,100,000 PLN
2024 – 2,000,000 PLN
Boehringer Ingelheim Poland is a leading pharmaceutical company with over 230 employees, operating a Global Business Services center in Wrocław and conducting R&D, manufacturing, and commercial activities. It focuses on innovative medicinal products for human and veterinary medicine.